Results

#ASH18: Regeneron’s bispecific REGN1979 offers eye-catching 80% CR rate in follicular lymphoma, spurring swift shift to pivotal study

As one of the world’s top — and certainly best paid — antibody drug developers, Regeneron’s George Yancopoulos tends to attract a considerable amount of attention when he gets excited by one of his clinical projects. And today you’ll find him eagerly touting a bispecific therapy that the R&D chief has sky-high hopes for.

Evidently with good reason.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 35,300+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->